Absolutely, 1st line in ER+/HER2- is very big and the HR=0.37, 95% CI 0.21-0.63, p<0.001 on PFS is very impressive. Of course, the FDA may want two co-primary endpoints - PFS and OS in phase III.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.